Literature DB >> 2125544

Clinical experience with the progestogen-only pill.

M Broome1, K Fotherby.   

Abstract

Experience with the progestogen-only pill (POP) in a family planning clinic is presented. From the clinic records, 408 women were identified who had opted to use a POP. Of these, 50 women had used the POP during lactation and these were excluded from the analysis. The remaining 358 women used the POP for up to 150 months, giving a total of 18,125 women-months of use. Three pregnancies occurred, giving a Pearl Index of 0.2 per 100 women-years. Non-menstrual side effects were minor and were reported by 77 women. For the women who discontinued the POP, the main reason was menstrual irregularity (47.5%). However, despite the long-term use by most of the women, almost 40% maintained a mostly regular menstrual pattern. Our findings suggest that the POP provides a very acceptable method of oral contraception for many women and that it should be more actively promoted.

Entities:  

Keywords:  Bleeding; Clinical Research; Contraception; Contraception Termination; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--administraction and dosage; Contraceptive Agents--side effects; Contraceptive Methods; Contraceptive Usage; Delivery Of Health Care; Demographic Factors; Developed Countries; Diseases; England; Ethynodiol Diacetate--administraction and dosage; Europe; Evaluation; Family Planning; Family Planning Centers; Female Contraception; Health; Health Facilities; Levonorgestrel--administraction and dosage; Menstruation Disorders; Method Acceptability; Norethindrone--administraction and dosage; Northern Europe; Oral Contraceptives; Population; Population Characteristics; Research Methodology; Signs And Symptoms; United Kingdom

Mesh:

Substances:

Year:  1990        PMID: 2125544     DOI: 10.1016/0010-7824(90)90077-9

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  4 in total

1.  Randomized, Crossover and Single-Dose Bioquivalence Study of Two Oral Desogestrel Formulations (Film-Coated Tablets of 75 μg) in Healthy Female Volunteers.

Authors:  María Ángeles Pena; Emilio Sanz; Silvia Francisco; Ainhara Alonso; Zurine Abajo; Izaskun Felipe; Jaume Pascual; Digna Tost; Sandra Bailac
Journal:  Sci Pharm       Date:  2012-03-01

2.  Norethindrone is superior to combined oral contraceptive pills in short-term delay of menses and onset of breakthrough bleeding: a randomized trial.

Authors:  Joshua Dean; Katherine J Kramer; Fauzia Akbary; Shaunte Wade; Maik Hüttemann; Jay M Berman; Maurice-Andre Recanati
Journal:  BMC Womens Health       Date:  2019-05-28       Impact factor: 2.809

3.  New Contraception Update - Annovera, Phexxi, Slynd, and Twirla.

Authors:  Courtney C Baker; Melissa J Chen
Journal:  Curr Obstet Gynecol Rep       Date:  2022-01-06

Review 4.  Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates.

Authors:  Jennifer Villavicencio; Rebecca H Allen
Journal:  Open Access J Contracept       Date:  2016-03-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.